Aml смотреть последние обновления за сегодня на .
Learn more about AML at 🤍 This animation provides an overview of acute myeloid leukemia (AML), a blood and bone marrow cancer that happens to persons who have too many abnormal cells called myeloblasts. It describes the causes, risk factors, and symptoms of AML, as well as the subtype of AML called acute promyelocytic leukemia (commonly referred to as APL or APML).
😍🖼Animated Mnemonics (Picmonic): 🤍 - With Picmonic, get your life back by studying less and remembering more. Medical and Nursing students say that Picmonic is the most comprehensive and effective way to bridge learning and test prep... Disclaimer: I use affiliate links.... ►👨🏫💊Antibiotics Lectures: 🤍 ... Check out my brand new "Electrolytes" course at 🤍 and use the PROMO code: ELECTROLYTES50 to get a 50% discount. ► Right Now! You can get access to all my hand-written hematology video notes (the notes that I use on my videos) on Patreon...There is a direct link through which you can view, download, print and enjoy! Go to 🤍 To get access to leukemia videos right now, before anyone else...Go to my patreon page 🤍patreon.com/medicosis AML = Acute Myeloid Leukemia (or Acute Myelogenous leukemia) If you like my videos, please consider leaving a tip at 🤍 ► Visit my website: 🤍 My Favorite Productivity App: 🤍 📱Save on your mobile phone bill: 🤍
What is acute leukemia? It is a condition in which the hematopoietic stem cells in the body become abnormal and accumulate in the bone marrow and blood serum. Acute leukemia can be split into two types: myeloid or lymphoblastic. This depends on the lineage of the hematopoietic stem cell. This video discusses the pathophysiology and major clinical signs and symptoms.
Learn more about AML at 🤍 In this video, Dr. Sandra Kurtin, an expert on acute myeloid leukemia (AML), explains that the outlook or prognosis for someone with AML depends on the type they have. Some types of AML have a favorable outlook or prognosis, while other types, including treatment-related or secondary AML, have a poor outlook without a stem cell transplant. Younger people with AML usually have a better outlook than older people. Learning about your AML subtype and any genetic changes you have is very important for understanding your AML prognosis.
Learn more about AML at 🤍 This animation provides an overview of treatment failure and relapse in acute myeloid leukemia (AML). Treatment failure occurs when your AML treatment is not successful in eliminating all the leukemia from your bone marrow after initial therapy (induction chemotherapy). It could also mean that the leukemia came back (relapsed) after being well controlled after chemotherapy and entering a state known as remission. You can learn about how often AML relapse occurs, who is at risk, why complete remission is less common in older adults, as well as cytogenetics and AML treatment failure.
When Kenneth Woo received his AML diagnosis, he felt as if he'd received a death sentence. But after undergoing chemotherapy, two clinical trials and a stem cell transplant as part of his AML treatment at The University of Texas MD Anderson Cancer Center, he has been cancer-free for a decade. In this video, Woo and his wife Clara share their advice for coping with a new AML diagnosis, making sure you're getting the best AML treatment and living life fully in spite of AML. Learn about MD Anderson's AML/MDS Moon Shot: 🤍 Request an appointment at MD Anderson by calling 1-877-632-6789 or online: 🤍
This is a recording of a webinar aired on Monday, October 17, 2022 Speaker: Dr. Fred Appelbaum, Executive Vice President of Fred Hutch Cancer Center and Associate Director for Clinical Research at the Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium.
Learn more about AML at 🤍 This animation explains the current treatments for acute myeloid leukemia (AML). It also explains key terms used in AML treatment such as complete remission, measurable residual disease (MRD), hematologic recovery, cytogenetic response, and molecular response. Treatment options are described, such as induction chemotherapy, consolidation chemotherapy, stem cell transplant, and targeted therapy. It’s important to discuss all treatment options with your doctor or cancer care team, so you can make the best decisions that are right for you.
Learn more about AML at 🤍 This animation provides an overview of maintenance and continuous treatment for acute myeloid leukemia (AML). Maintenance therapy is additional chemotherapy after induction and consolidation therapy has led to remission. It may help prevent relapse or prolong the remission and help people live longer. You can learn about the three common phases of AML treatment (induction, consolidation, and maintenance) as well as treatment options that are currently available. Depending on your AML and general health, some therapies may help keep your AML stable and prolong your survival even if you still have AML, provided you still have some healthy bone marrow cells. It's important to discuss all treatment options with your doctor or cancer care team, so you can make the best decisions that are right for you.
😍🖼Animated Mnemonics (Picmonic): 🤍 - With Picmonic, get your life back by studying less and remembering more. Medical and Nursing students say that Picmonic is the most comprehensive and effective way to bridge learning and test prep... Disclaimer: I use affiliate links.... ►👨🏫💊Antibiotics Lectures: 🤍 ... Check out my brand new "Electrolytes" course at 🤍 and use the PROMO code: ELECTROLYTES50 to get a 50% discount. ► Right Now! You can get access to all my hand-written hematology video notes (the notes that I use on my videos) on Patreon...There is a direct link through which you can view, download, print and enjoy! Go to 🤍 To get access to leukemia videos right now, before anyone else...Go to my patreon page 🤍patreon.com/medicosis If you like my videos, please consider leaving a tip at 🤍 ► Visit my website: 🤍 My Favorite Productivity App: 🤍 📱Save on your mobile phone bill: 🤍
Earn CME for related activities: 🤍 In this webcast from the 'MRD in Hematologic Malignancies: Testing Considerations and Challenges' symposium, Dr. Gail J. Roboz discusses the role of minimal residual disease (MRD) testing in the treatment of acute myeloid leukemia (AML).
Learn more about AML at 🤍 Dr. Sandra Kurtin, an expert on acute myeloid leukemia (AML), describes some of the symptoms of AML in this video. Symptoms can come on suddenly and include fever, shortness of breath, weakness, weakness, dizziness, and headaches. You may feel like you have the flu. You might also bruise or bleed easily. Some people have milder symptoms that appear over time, such as being very tired. Changes in the various types of blood cells produce different symptoms.
Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, however, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In acute myeloid leukemia (AML), there are too many of a specific type of white blood cell called a myeloblast. AML is the most common type of acute leukemia in adults. This type of cancer usually gets worse quickly if it is not treated. Possible risk factors include smoking, previous chemotherapy treatment, and exposure to radiation. Symptoms of AML include: • Fever • Shortness of breath • Easy bruising or bleeding • Bleeding under the skin • Weakness or feeling tired • Weight loss or loss of appetite Tests that examine the blood and bone marrow diagnose AML. Treatments include chemotherapy, other drugs, radiation therapy, stem cell transplants, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Once the leukemia is in remission, you need additional treatment to make sure that it does not come back. NIH: National Cancer Institute
Learn more about MDS at 🤍 MDS experts, Dr Rafael Bejar and Dr Casey O’Connell, discuss how acute myeloid leukemia (AML) relates to MDS. About 30 percent of people with MDS develop a life-threatening blood cancer called AML. The risk of AML depends on the type of MDS you have and other factors. To help confirm a diagnosis of AML, a bone marrow biopsy is performed to capture all the changes (including genetic) that led to the condition.
In this webcast, Dr. Florian Kuchenbauer will explain modern approaches to classification and treatment of acute myeloid leukemia. He will further discuss clinical trials that changed treatment paradigms and explain how research opens new treatment avenues. This interactive and easy to understand webcast is aimed at patients, relatives, friends and everybody who is interested in acute myeloid leukemia.
Learn more about AML at 🤍 In this video, Dr. Sandra Kurtin, an expert on acute myeloid leukemia, explains how your doctor may find AML. You may see your doctor for symptoms such as being very tired or bleeding or bruising easily. Your cancer doctor may diagnose AML if you are already being treated for myelodysplastic syndrome (MDS), or had previous cancer treatment that can lead to treatment-related AML (tAML). An examination, blood tests, and a bone marrow biopsy are used to find signs, including genetic changes, and make the diagnosis.
Learn more about AML at 🤍 In this video, expert Dr. David Steensma explains that there are a number of types of acute myeloid leukemia (AML). Types include treatment-related AML, also called secondary or therapy-related AML (tAML), AML with myelodysplasia-related changes (AML-MRC), and acute promyelocytic leukemia (APL). The different types of AML can make it a challenge to match the treatment to each patient.
Learn more about AML at 🤍 In this video, Dr. David Steensma, an expert on acute myeloid leukemia, explains that doctors do not measure how serious AML is by “staging” it. Solid tumors are measured by their size and how far they have spread in the body. This is called staging. But AML affects the bone marrow and blood. Because it affects the blood, it is usually widespread by the time doctors find it.
Get exclusive access to our latest content as soon as it's filmed for free at 🤍 HealthTree University for acute myeloid leukemia offers a comprehensive online curriculum with lessons, quizzes and course discussion. Create a free account today to track your progress, earn points to win prizes, and stay up to date on the latest advancements in treating AML! Topics covered include: AML basics, allogeneic stem cell transplant, AML genetics, relapsed and refractory AML and much more. We've partnered with AML experts to help you learn quickly. Improve the way you navigate your disease and obtain better outcomes with HealthTree University. Stay up to date on the latest AML news through our newsletter! 🤍 Follow HealthTree: Twitter: 🤍 Facebook: 🤍 Instagram: 🤍
Learn more about AML at 🤍 Dr. Sandra Kurtin, an expert on acute myeloid leukemia (AML), describes the induction and consolidation phases of chemotherapy treatment for this disease. The first phase of treatment is called induction chemotherapy. It is designed to eliminate the blasts, or abnormal cells, that are too numerous in the bone marrow. Induction chemotherapy is usually done in the hospital. Once the blast numbers are reduced, you have additional chemotherapy called “consolidation” to make sure the levels of these cells remain low.
Daniel Pollyea, MD, MS, of the University of Colorado, Denver, CO, outlines the use of venetoclax, a BCL-2 inhibitor, in acute myeloid leukemia (AML) and caveats associated with its use, including moving this treatment beyond its approved indication in unfit, relapsed/refractory AML. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Learn more about AML at 🤍 This animation explains the tests that doctors use to diagnose acute myeloid leukemia (AML), AML with myelodysplasia-related changes (AML-MRC) and treatment-related AML (tAML). It describes the examination, blood tests, bone marrow tests, genetic tests, imaging tests, and other diagnostic interventions. These tests may be ordered to help identify what subtype of AML a person has and whether it has spread outside of the blood and bone marrow.
Lillian Dooies was diagnosed with acute myeloid leukemia (AML) in January 2013. She was diagnosed in her hometown of West Palm Beach, Florida. and her doctor there recommended that she should seek AML treatment at MD Anderson. Upon arriving at MD Anderson, she immediately went through 30 days of chemotherapy to get her leukemia into remission, and received a bone marrow transplant in April 2013. Her transplant donor was Jenny Salimi of Denver, Colorado. After a year of corresponding anonymously, Jenny and Lillian couldn't wait to meet each other in person. Three years later, they are still very close and see each other often. Recently, Jenny came to visit MD Anderson with Lillian so she could meet all the doctors and nurses, and see where Lillian received her treatment. Watch their story and learn about the transplant process and what brought these two so close together. Register to become a bone marrow donor: 🤍 Learn about MD Anderson's MDS and AML Moon Shot: 🤍 Request an appointment at MD Anderson by calling 1-877-632-6789 or online at: 🤍
Selina M. Luger, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, discusses the importance of defining patient risk group when making decisions about consolidation therapy in acute myeloid leukemia (AML). Prof. Luger explains how cytarabine is used to approach remission therapy for the core binding factor AML risk group, whereas allogeneic bone marrow transplants are usually recommended as remission therapy for patients with poor prognostic factors. Prof. Luger further comments on approaches for intermediate risk groups, where measurable residual disease (MRD), karyotype and molecular analysis are required to determine a suitable consolidation therapy. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
UCLA hematologist and oncologist Caspian Oliai, MD, MS discuss current and new strategies for treating acute myeloid leukemia (AML), including available clinical trials. Conversation moderated by Leila Evangelista from the Leukemia & Lymphoma Society. Learn more about our Closer to a Cure series: 🤍
Meet Melissa Ruffino, teacher, sister, daughter, and survivor of Acute Myeloid Leukemia. When she was diagnosed at the age of 32, she immediately moved from Austin to Dallas to begin treatment at UT Southwestern's Bone Marrow Transplant Program. After two rounds of chemotherapy, she underwent a bone marrow transplant that has now given her more than one-thousand days of life. For information about becoming a donor, visit bethematch.org.
Rory Shallis, MD, Yale Cancer Center, West Haven, CT, shares his insights on treatment algorithms for patients with acute myeloid leukemia (AML), drawing focus on the decision-making process, including whether patients are eligible for intensive therapy, or would benefit from less intensive options. Dr Shallis then discusses the importance of considering disease biology when choosing treatment regimens, mentioning the impact of mutations such as FLT3, IDH1, and IDH2 in guiding this choice. To conclude, Dr Shallis mentions the importance of deciding whether a patient is eligible for allogeneic hematopoietic stem cell transplant (allo-HSCT) and how this may influence survival outcome. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
Learn more about AML at 🤍 Dr. David Steensma explains that the outlook, or prognosis, varies widely from cure to a few months or years of life. The factors influencing the outlook include age, type of AML (AML subtype), general health and genetic changes present in the blasts. Younger patients and those with de novo AML often do better than those with treatment-related AML (tAML) or AML with myelodysplastic changes (AML-MRC).
Minerva was working as a therapist and on the road to earning her PhD when she was diagnosed with acute myeloid leukemia (AML). Thanks to Dr. Ellen Ritchie and the Leukemia Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital, she's now in remission and using her cancer experience to help others navigate difficult situations.
Acute myeloid leukemia (AML) is the most common leukemia. For the past 5-6 years, tremendous development and improvement have taken place. In particular, discoveries of gene mutations of leukemic cells lead to development of specific inhibitors targeting the mutated genes. It also was found that the molecular genetics of leukemia are associated with prognosis. Patient who belong to poor prognostic group are treated with more intense therapy such as allogeneic hematopoietic stem cell transplantation while favorable group can be managed without stem cell transplantation. I present the most updated and comprehensive review in diagnosis and treatment of AML
Curtis Lachowiez, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the tools and platforms used for the diagnosis of acute myeloid leukemia (AML). Morphological assessment of the bone marrow is the main diagnostic strategy used to identify the type of leukemia a patient has. As technology has advanced, several additional tools are used to provide more detail on a patient’s disease. Cytogenetic and molecular genetic analyses are conducted using fluorescence in situ hybridization (FISH), next-generation sequencing, and flow cytometry. Dr Lachowiez explains the extra information that can be provide by the identification of prognostic and predictive genetic changes using these techniques. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Learn more about AML at 🤍 In this video, expert Dr. Sandra Kurtin describes some of the risk factors for acute myeloid leukemia, or AML. Age is a main risk factor, and most people diagnosed with AML are over 65. Other risk factors include smoking, having radiation therapy or some types of chemotherapy, being exposed to a chemical called benzene and having certain genetic changes.
Harry Erba, MD, PhD, and Naval G. Daver, MD, elucidate the differential impact that FLT3 internal tandem duplication and tyrosine kinase domain mutations have on the prognosis and management of acute myeloid leukemia (AML).
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel Aviv, Israel, discusses the outcomes of patients with secondary acute myeloid leukemia (sAML) undergoing stem cell transplantation. Prof. Nagler first explains the higher relapse rates and worse overall survival (OS) observed in patients with sAML versus de novo AML, and further comments on novel agents being investigated to improve these outcomes, including CPX-351. To conclude, Prof. Nagler highlights a study which compared various myeloablative conditioning regimens in sAML, and the importance of conducting more research in this space. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.